Trial Profile
Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Mozafancogene autotemcel (Primary)
- Indications Fanconi's anaemia
- Focus Therapeutic Use
- Acronyms FANCOLEN-I
- 06 Nov 2023 According to a Rocket Pharmaceuticals media release, Product filings for RP-L102 anticipated in the first half of 2024 in the U.S. and Europe. The company is finalizing the CMC package with the FDA.
- 09 Jan 2023 According to a Rocket Pharmaceuticals media release, BLA filling for FA is on track for Q4 2023.
- 13 May 2021 According to a Rocket Pharmaceuticals media release, results from this study were presented at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2021.